Diclofenac Patches Market - Size, Share, Outlook, and Forecast till 2026

Diclofenac patches contains a nonsteroidal anti-inflammatory drug (NSAID) called diclofenac. Diclofenac helps reduce pain by reducing the chemicals in the body that cause pain and inflammation. Diclofenac patches help in relieving pain caused by minor sprains, strains, or bruising, however, they are associated with serious cardiovascular and intestinal issues.

Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID), which is prescribed for people that suffer from pain such as sprains and strains. These aches and pains have high incidence rate and is commonly prevalent among people of all age groups. Thus, the demand for these patches is high, which in turn, is boosting growth of the diclofenac patches market size.

However, people suffering from asthma or a severe allergic reaction caused by aspirin, diclofenac (Cataflam, Voltaren), or another non-steroidal anti-inflammatory drug (NSAID) are cautioned against the use of this patch. The patch also proves harmful before and after having heart bypass surgery or coronary artery bypass graft, or CABG. This in turn, limits the number of patients that can use this patch, which in turn, poses as a major factor restraining growth of the diclofenac patches market.

The list of disease history that diclofenac does not support includes allergy to any drugs, heart disease, congestive heart failure, high blood pressure, history of heart attack or stroke, a history of stomach ulcer or bleeding, liver or kidney disease, blood clotting disorder, asthma or polyps in the nose. Furthermore, people who smoke daily may also develop complications due to application of diclofenac. These factors in turn hamper growth of the diclofenac patches market
Request for Sample Copy of Research Report:https://www.worldwidemarketreports.com/sample/195634

FLECTOR® PATCH is a diclofenac epolamine topical patch, which is a registered trademark of IBSA Institut Biochimique SA, licensed by Alpharma Pharmaceuticals LLC—a subsidiary of Pfizer Inc. The drug is effective at reliving pain from minor strains.
Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/195634
Zydus Cadila Healthcare—an India-based company launched NuPatch, which is India's first indigenously manufactured Diclofenac transdermal patch for pain relief. NuPatch’s drug delivery system, through the transdermal delivery route, addresses two major problems posed by the traditional oral dosage form - local gastric irritation and the need to consume two to three doses in a day. Nupatch contains a 100 mg of Diclofenac, which is well-known and commonly used painkiller. Instead of the thrice daily dosage as in the case of the oral dosage form, NuPatch is only required to be applied once a day and provides extended pain relief for 24 hours at a stretch.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

1001 4th Ave,
#3200
Seattle, WA 98154,
U.S

This release was published on openPR.